nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentoxifylline—systemic scleroderma—psoriasis	0.828	1	CtDrD
Pentoxifylline—CYP1A2—Clobetasol propionate—psoriasis	0.025	0.656	CbGbCtD
Pentoxifylline—CYP1A2—Methoxsalen—psoriasis	0.0131	0.344	CbGbCtD
Pentoxifylline—NT5E—Purine catabolism—CAT—psoriasis	0.00212	0.139	CbGpPWpGaD
Pentoxifylline—NT5E—Purine metabolism—CAT—psoriasis	0.000815	0.0536	CbGpPWpGaD
Pentoxifylline—NT5E—HIF-1-alpha transcription factor network—CP—psoriasis	0.000798	0.0524	CbGpPWpGaD
Pentoxifylline—PDE5A—Nitric oxide stimulates guanylate cyclase—NOS2—psoriasis	0.000577	0.0379	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—SERPINB8—psoriasis	0.000422	0.0278	CbGpPWpGaD
Pentoxifylline—NT5E—Nucleotide metabolism—CAT—psoriasis	0.00041	0.0269	CbGpPWpGaD
Pentoxifylline—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000373	0.0245	CbGpPWpGaD
Pentoxifylline—NT5E—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000364	0.0239	CbGpPWpGaD
Pentoxifylline—NT5E—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000339	0.0223	CbGpPWpGaD
Pentoxifylline—ADORA1—G alpha (i) signalling events—HCAR2—psoriasis	0.000268	0.0176	CbGpPWpGaD
Pentoxifylline—NT5E—Differentiation Pathway—VEGFA—psoriasis	0.000253	0.0166	CbGpPWpGaD
Pentoxifylline—ADORA2B—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000251	0.0165	CbGpPWpGaD
Pentoxifylline—PDE5A—Platelet homeostasis—NOS2—psoriasis	0.000225	0.0148	CbGpPWpGaD
Pentoxifylline—NT5E—HIF-1-alpha transcription factor network—JUN—psoriasis	0.000225	0.0148	CbGpPWpGaD
Pentoxifylline—ADORA1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000213	0.014	CbGpPWpGaD
Pentoxifylline—NT5E—HIF-1-alpha transcription factor network—VEGFA—psoriasis	0.000196	0.0129	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR ligand binding—HCAR2—psoriasis	0.000191	0.0126	CbGpPWpGaD
Pentoxifylline—NT5E—Differentiation Pathway—IL6—psoriasis	0.000175	0.0115	CbGpPWpGaD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000165	0.0108	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR ligand binding—HCAR2—psoriasis	0.000162	0.0107	CbGpPWpGaD
Pentoxifylline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000155	0.0102	CbGpPWpGaD
Pentoxifylline—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000153	0.0101	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—NDUFA5—psoriasis	0.000146	0.00957	CbGpPWpGaD
Pentoxifylline—ADORA1—G alpha (i) signalling events—CCL20—psoriasis	0.000139	0.00916	CbGpPWpGaD
Pentoxifylline—ADORA2B—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00013	0.00856	CbGpPWpGaD
Pentoxifylline—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000126	0.00826	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR ligand binding—HCAR2—psoriasis	0.000125	0.00824	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—CYP2S1—psoriasis	0.000124	0.00814	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—ITGAL—psoriasis	0.000123	0.00807	CbGpPWpGaD
Pentoxifylline—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.000111	0.00728	CbGpPWpGaD
Pentoxifylline—ADORA1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000111	0.00728	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—HCAR2—psoriasis	0.000108	0.00709	CbGpPWpGaD
Pentoxifylline—ADORA2B—C-MYB transcription factor network—CD4—psoriasis	0.000105	0.00688	CbGpPWpGaD
Pentoxifylline—ADORA2A—Monoamine Transport—TNF—psoriasis	9.97e-05	0.00655	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR ligand binding—CCL20—psoriasis	9.92e-05	0.00652	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—HCAR2—psoriasis	9.8e-05	0.00644	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—HCAR2—psoriasis	9.8e-05	0.00644	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—HCAR2—psoriasis	9.18e-05	0.00603	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—HCAR2—psoriasis	9.07e-05	0.00596	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—HCAR2—psoriasis	8.9e-05	0.00585	CbGpPWpGaD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	8.55e-05	0.00562	CbGpPWpGaD
Pentoxifylline—Decreased appetite—Mycophenolate mofetil—psoriasis	8.55e-05	0.000719	CcSEcCtD
Pentoxifylline—Anorexia—Hydrocortisone—psoriasis	8.54e-05	0.000718	CcSEcCtD
Pentoxifylline—Diarrhoea—Mycophenolic acid—psoriasis	8.53e-05	0.000717	CcSEcCtD
Pentoxifylline—Conjunctivitis—Methotrexate—psoriasis	8.49e-05	0.000714	CcSEcCtD
Pentoxifylline—Immune system disorder—Prednisone—psoriasis	8.48e-05	0.000713	CcSEcCtD
Pentoxifylline—Malaise—Dexamethasone—psoriasis	8.46e-05	0.000711	CcSEcCtD
Pentoxifylline—Malaise—Betamethasone—psoriasis	8.46e-05	0.000711	CcSEcCtD
Pentoxifylline—Oedema—Triamcinolone—psoriasis	8.44e-05	0.000709	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Triamcinolone—psoriasis	8.44e-05	0.000709	CcSEcCtD
Pentoxifylline—ADORA1—GPCR ligand binding—CCL20—psoriasis	8.44e-05	0.00554	CbGpPWpGaD
Pentoxifylline—Constipation—Mycophenolate mofetil—psoriasis	8.41e-05	0.000707	CcSEcCtD
Pentoxifylline—Arrhythmia—Prednisone—psoriasis	8.38e-05	0.000705	CcSEcCtD
Pentoxifylline—Infection—Triamcinolone—psoriasis	8.38e-05	0.000705	CcSEcCtD
Pentoxifylline—Sweating—Methotrexate—psoriasis	8.37e-05	0.000704	CcSEcCtD
Pentoxifylline—Hypotension—Hydrocortisone—psoriasis	8.37e-05	0.000704	CcSEcCtD
Pentoxifylline—ADORA1—Signaling by GPCR—HCAR2—psoriasis	8.33e-05	0.00548	CbGpPWpGaD
Pentoxifylline—Feeling abnormal—Cyclosporine—psoriasis	8.31e-05	0.000699	CcSEcCtD
Pentoxifylline—Shock—Triamcinolone—psoriasis	8.3e-05	0.000698	CcSEcCtD
Pentoxifylline—Insomnia—Prednisolone—psoriasis	8.3e-05	0.000698	CcSEcCtD
Pentoxifylline—Hepatobiliary disease—Methotrexate—psoriasis	8.26e-05	0.000695	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Cyclosporine—psoriasis	8.24e-05	0.000693	CcSEcCtD
Pentoxifylline—Dizziness—Mycophenolic acid—psoriasis	8.24e-05	0.000693	CcSEcCtD
Pentoxifylline—Epistaxis—Methotrexate—psoriasis	8.24e-05	0.000693	CcSEcCtD
Pentoxifylline—PDE4B—Signaling by GPCR—HCAR2—psoriasis	8.24e-05	0.00541	CbGpPWpGaD
Pentoxifylline—Tachycardia—Triamcinolone—psoriasis	8.23e-05	0.000692	CcSEcCtD
Pentoxifylline—Erythema—Prednisone—psoriasis	8.17e-05	0.000687	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Hydrocortisone—psoriasis	8.16e-05	0.000686	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Triamcinolone—psoriasis	8.16e-05	0.000686	CcSEcCtD
Pentoxifylline—Convulsion—Dexamethasone—psoriasis	8.13e-05	0.000683	CcSEcCtD
Pentoxifylline—Convulsion—Betamethasone—psoriasis	8.13e-05	0.000683	CcSEcCtD
Pentoxifylline—Feeling abnormal—Mycophenolate mofetil—psoriasis	8.1e-05	0.000682	CcSEcCtD
Pentoxifylline—Insomnia—Hydrocortisone—psoriasis	8.1e-05	0.000681	CcSEcCtD
Pentoxifylline—Hypertension—Betamethasone—psoriasis	8.1e-05	0.000681	CcSEcCtD
Pentoxifylline—Hypertension—Dexamethasone—psoriasis	8.1e-05	0.000681	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	8.04e-05	0.000676	CcSEcCtD
Pentoxifylline—Urticaria—Cyclosporine—psoriasis	8.01e-05	0.000673	CcSEcCtD
Pentoxifylline—Myalgia—Betamethasone—psoriasis	7.98e-05	0.000672	CcSEcCtD
Pentoxifylline—Myalgia—Dexamethasone—psoriasis	7.98e-05	0.000672	CcSEcCtD
Pentoxifylline—Body temperature increased—Cyclosporine—psoriasis	7.97e-05	0.00067	CcSEcCtD
Pentoxifylline—Abdominal pain—Cyclosporine—psoriasis	7.97e-05	0.00067	CcSEcCtD
Pentoxifylline—Anxiety—Betamethasone—psoriasis	7.96e-05	0.000669	CcSEcCtD
Pentoxifylline—Anxiety—Dexamethasone—psoriasis	7.96e-05	0.000669	CcSEcCtD
Pentoxifylline—Vomiting—Mycophenolic acid—psoriasis	7.92e-05	0.000666	CcSEcCtD
Pentoxifylline—Discomfort—Dexamethasone—psoriasis	7.89e-05	0.000663	CcSEcCtD
Pentoxifylline—Discomfort—Betamethasone—psoriasis	7.89e-05	0.000663	CcSEcCtD
Pentoxifylline—Dyspepsia—Hydrocortisone—psoriasis	7.89e-05	0.000663	CcSEcCtD
Pentoxifylline—Haemoglobin—Methotrexate—psoriasis	7.88e-05	0.000663	CcSEcCtD
Pentoxifylline—Rash—Mycophenolic acid—psoriasis	7.86e-05	0.000661	CcSEcCtD
Pentoxifylline—Dermatitis—Mycophenolic acid—psoriasis	7.85e-05	0.00066	CcSEcCtD
Pentoxifylline—Haemorrhage—Methotrexate—psoriasis	7.84e-05	0.000659	CcSEcCtD
Pentoxifylline—Hepatitis—Methotrexate—psoriasis	7.84e-05	0.000659	CcSEcCtD
Pentoxifylline—Urticaria—Mycophenolate mofetil—psoriasis	7.81e-05	0.000657	CcSEcCtD
Pentoxifylline—Headache—Mycophenolic acid—psoriasis	7.81e-05	0.000657	CcSEcCtD
Pentoxifylline—Decreased appetite—Hydrocortisone—psoriasis	7.79e-05	0.000655	CcSEcCtD
Pentoxifylline—Abdominal pain—Mycophenolate mofetil—psoriasis	7.77e-05	0.000654	CcSEcCtD
Pentoxifylline—Body temperature increased—Mycophenolate mofetil—psoriasis	7.77e-05	0.000654	CcSEcCtD
Pentoxifylline—Vision blurred—Prednisone—psoriasis	7.7e-05	0.000647	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.69e-05	0.000646	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Dexamethasone—psoriasis	7.65e-05	0.000644	CcSEcCtD
Pentoxifylline—Oedema—Betamethasone—psoriasis	7.65e-05	0.000644	CcSEcCtD
Pentoxifylline—Oedema—Dexamethasone—psoriasis	7.65e-05	0.000644	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Betamethasone—psoriasis	7.65e-05	0.000644	CcSEcCtD
Pentoxifylline—Insomnia—Triamcinolone—psoriasis	7.63e-05	0.000642	CcSEcCtD
Pentoxifylline—Infection—Dexamethasone—psoriasis	7.6e-05	0.00064	CcSEcCtD
Pentoxifylline—Infection—Betamethasone—psoriasis	7.6e-05	0.00064	CcSEcCtD
Pentoxifylline—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	7.59e-05	0.00499	CbGpPWpGaD
Pentoxifylline—Ill-defined disorder—Prednisone—psoriasis	7.58e-05	0.000637	CcSEcCtD
Pentoxifylline—Feeling abnormal—Prednisolone—psoriasis	7.56e-05	0.000636	CcSEcCtD
Pentoxifylline—Anaemia—Prednisone—psoriasis	7.55e-05	0.000635	CcSEcCtD
Pentoxifylline—Shock—Dexamethasone—psoriasis	7.53e-05	0.000633	CcSEcCtD
Pentoxifylline—Shock—Betamethasone—psoriasis	7.53e-05	0.000633	CcSEcCtD
Pentoxifylline—Dyspnoea—Triamcinolone—psoriasis	7.52e-05	0.000633	CcSEcCtD
Pentoxifylline—Agitation—Prednisone—psoriasis	7.51e-05	0.000631	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Dexamethasone—psoriasis	7.49e-05	0.00063	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Betamethasone—psoriasis	7.49e-05	0.00063	CcSEcCtD
Pentoxifylline—Tachycardia—Betamethasone—psoriasis	7.47e-05	0.000628	CcSEcCtD
Pentoxifylline—Tachycardia—Dexamethasone—psoriasis	7.47e-05	0.000628	CcSEcCtD
Pentoxifylline—Angioedema—Prednisone—psoriasis	7.46e-05	0.000628	CcSEcCtD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	7.43e-05	0.00489	CbGpPWpGaD
Pentoxifylline—Hypersensitivity—Cyclosporine—psoriasis	7.43e-05	0.000625	CcSEcCtD
Pentoxifylline—Dyspepsia—Triamcinolone—psoriasis	7.43e-05	0.000624	CcSEcCtD
Pentoxifylline—Nausea—Mycophenolic acid—psoriasis	7.4e-05	0.000622	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Dexamethasone—psoriasis	7.4e-05	0.000622	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Betamethasone—psoriasis	7.4e-05	0.000622	CcSEcCtD
Pentoxifylline—Feeling abnormal—Hydrocortisone—psoriasis	7.38e-05	0.000621	CcSEcCtD
Pentoxifylline—Malaise—Prednisone—psoriasis	7.37e-05	0.000619	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Hydrocortisone—psoriasis	7.33e-05	0.000616	CcSEcCtD
Pentoxifylline—Anorexia—Dexamethasone—psoriasis	7.3e-05	0.000614	CcSEcCtD
Pentoxifylline—Anorexia—Betamethasone—psoriasis	7.3e-05	0.000614	CcSEcCtD
Pentoxifylline—Urticaria—Prednisolone—psoriasis	7.29e-05	0.000613	CcSEcCtD
Pentoxifylline—Hypersensitivity—Mycophenolate mofetil—psoriasis	7.25e-05	0.000609	CcSEcCtD
Pentoxifylline—Asthenia—Cyclosporine—psoriasis	7.23e-05	0.000608	CcSEcCtD
Pentoxifylline—Hypotension—Dexamethasone—psoriasis	7.15e-05	0.000602	CcSEcCtD
Pentoxifylline—Hypotension—Betamethasone—psoriasis	7.15e-05	0.000602	CcSEcCtD
Pentoxifylline—Pruritus—Cyclosporine—psoriasis	7.13e-05	0.0006	CcSEcCtD
Pentoxifylline—Urticaria—Hydrocortisone—psoriasis	7.12e-05	0.000599	CcSEcCtD
Pentoxifylline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.12e-05	0.00468	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—HCAR2—psoriasis	7.09e-05	0.00466	CbGpPWpGaD
Pentoxifylline—Immune system disorder—Methotrexate—psoriasis	7.08e-05	0.000596	CcSEcCtD
Pentoxifylline—Abdominal pain—Hydrocortisone—psoriasis	7.08e-05	0.000596	CcSEcCtD
Pentoxifylline—Body temperature increased—Hydrocortisone—psoriasis	7.08e-05	0.000596	CcSEcCtD
Pentoxifylline—Convulsion—Prednisone—psoriasis	7.08e-05	0.000595	CcSEcCtD
Pentoxifylline—Asthenia—Mycophenolate mofetil—psoriasis	7.06e-05	0.000593	CcSEcCtD
Pentoxifylline—Hypertension—Prednisone—psoriasis	7.05e-05	0.000593	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.97e-05	0.000586	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Betamethasone—psoriasis	6.97e-05	0.000586	CcSEcCtD
Pentoxifylline—Pruritus—Mycophenolate mofetil—psoriasis	6.96e-05	0.000585	CcSEcCtD
Pentoxifylline—Myalgia—Prednisone—psoriasis	6.95e-05	0.000585	CcSEcCtD
Pentoxifylline—Feeling abnormal—Triamcinolone—psoriasis	6.95e-05	0.000585	CcSEcCtD
Pentoxifylline—Anxiety—Prednisone—psoriasis	6.93e-05	0.000583	CcSEcCtD
Pentoxifylline—Insomnia—Dexamethasone—psoriasis	6.92e-05	0.000582	CcSEcCtD
Pentoxifylline—Insomnia—Betamethasone—psoriasis	6.92e-05	0.000582	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	6.91e-05	0.000581	CcSEcCtD
Pentoxifylline—Diarrhoea—Cyclosporine—psoriasis	6.9e-05	0.00058	CcSEcCtD
Pentoxifylline—Discomfort—Prednisone—psoriasis	6.87e-05	0.000578	CcSEcCtD
Pentoxifylline—Erythema—Methotrexate—psoriasis	6.83e-05	0.000574	CcSEcCtD
Pentoxifylline—Hypersensitivity—Prednisolone—psoriasis	6.76e-05	0.000568	CcSEcCtD
Pentoxifylline—Dyspepsia—Betamethasone—psoriasis	6.74e-05	0.000567	CcSEcCtD
Pentoxifylline—Dyspepsia—Dexamethasone—psoriasis	6.74e-05	0.000567	CcSEcCtD
Pentoxifylline—Diarrhoea—Mycophenolate mofetil—psoriasis	6.73e-05	0.000566	CcSEcCtD
Pentoxifylline—Urticaria—Triamcinolone—psoriasis	6.7e-05	0.000564	CcSEcCtD
Pentoxifylline—Dysgeusia—Methotrexate—psoriasis	6.68e-05	0.000562	CcSEcCtD
Pentoxifylline—CYP1A2—Biological oxidations—CYP2S1—psoriasis	6.67e-05	0.00439	CbGpPWpGaD
Pentoxifylline—Body temperature increased—Triamcinolone—psoriasis	6.67e-05	0.000561	CcSEcCtD
Pentoxifylline—Dizziness—Cyclosporine—psoriasis	6.67e-05	0.000561	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Prednisone—psoriasis	6.67e-05	0.000561	CcSEcCtD
Pentoxifylline—Oedema—Prednisone—psoriasis	6.67e-05	0.000561	CcSEcCtD
Pentoxifylline—Decreased appetite—Betamethasone—psoriasis	6.65e-05	0.00056	CcSEcCtD
Pentoxifylline—Decreased appetite—Dexamethasone—psoriasis	6.65e-05	0.00056	CcSEcCtD
Pentoxifylline—Infection—Prednisone—psoriasis	6.62e-05	0.000557	CcSEcCtD
Pentoxifylline—Back pain—Methotrexate—psoriasis	6.6e-05	0.000555	CcSEcCtD
Pentoxifylline—Hypersensitivity—Hydrocortisone—psoriasis	6.6e-05	0.000555	CcSEcCtD
Pentoxifylline—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	6.58e-05	0.00433	CbGpPWpGaD
Pentoxifylline—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	6.57e-05	0.00432	CbGpPWpGaD
Pentoxifylline—Shock—Prednisone—psoriasis	6.56e-05	0.000552	CcSEcCtD
Pentoxifylline—ADORA2A—GPCR ligand binding—CCL20—psoriasis	6.51e-05	0.00428	CbGpPWpGaD
Pentoxifylline—Tachycardia—Prednisone—psoriasis	6.51e-05	0.000547	CcSEcCtD
Pentoxifylline—Dizziness—Mycophenolate mofetil—psoriasis	6.5e-05	0.000547	CcSEcCtD
Pentoxifylline—Skin disorder—Prednisone—psoriasis	6.48e-05	0.000545	CcSEcCtD
Pentoxifylline—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	6.47e-05	0.00425	CbGpPWpGaD
Pentoxifylline—Hyperhidrosis—Prednisone—psoriasis	6.44e-05	0.000542	CcSEcCtD
Pentoxifylline—ADORA2A—Signaling by GPCR—HCAR2—psoriasis	6.43e-05	0.00423	CbGpPWpGaD
Pentoxifylline—Vision blurred—Methotrexate—psoriasis	6.43e-05	0.000541	CcSEcCtD
Pentoxifylline—Asthenia—Hydrocortisone—psoriasis	6.43e-05	0.000541	CcSEcCtD
Pentoxifylline—ADORA1—Circadian rythm related genes—LEP—psoriasis	6.42e-05	0.00422	CbGpPWpGaD
Pentoxifylline—Vomiting—Cyclosporine—psoriasis	6.41e-05	0.000539	CcSEcCtD
Pentoxifylline—Rash—Cyclosporine—psoriasis	6.36e-05	0.000535	CcSEcCtD
Pentoxifylline—Anorexia—Prednisone—psoriasis	6.35e-05	0.000534	CcSEcCtD
Pentoxifylline—Dermatitis—Cyclosporine—psoriasis	6.35e-05	0.000534	CcSEcCtD
Pentoxifylline—Pruritus—Hydrocortisone—psoriasis	6.34e-05	0.000533	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Methotrexate—psoriasis	6.33e-05	0.000533	CcSEcCtD
Pentoxifylline—Headache—Cyclosporine—psoriasis	6.32e-05	0.000531	CcSEcCtD
Pentoxifylline—Anaemia—Methotrexate—psoriasis	6.31e-05	0.000531	CcSEcCtD
Pentoxifylline—Feeling abnormal—Dexamethasone—psoriasis	6.31e-05	0.00053	CcSEcCtD
Pentoxifylline—Feeling abnormal—Betamethasone—psoriasis	6.31e-05	0.00053	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Dexamethasone—psoriasis	6.26e-05	0.000526	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Betamethasone—psoriasis	6.26e-05	0.000526	CcSEcCtD
Pentoxifylline—Vomiting—Mycophenolate mofetil—psoriasis	6.25e-05	0.000526	CcSEcCtD
Pentoxifylline—Hypersensitivity—Triamcinolone—psoriasis	6.22e-05	0.000523	CcSEcCtD
Pentoxifylline—Rash—Mycophenolate mofetil—psoriasis	6.2e-05	0.000521	CcSEcCtD
Pentoxifylline—Dermatitis—Mycophenolate mofetil—psoriasis	6.19e-05	0.000521	CcSEcCtD
Pentoxifylline—Headache—Mycophenolate mofetil—psoriasis	6.16e-05	0.000518	CcSEcCtD
Pentoxifylline—Malaise—Methotrexate—psoriasis	6.16e-05	0.000518	CcSEcCtD
Pentoxifylline—Diarrhoea—Hydrocortisone—psoriasis	6.13e-05	0.000516	CcSEcCtD
Pentoxifylline—Leukopenia—Methotrexate—psoriasis	6.11e-05	0.000514	CcSEcCtD
Pentoxifylline—Urticaria—Betamethasone—psoriasis	6.08e-05	0.000511	CcSEcCtD
Pentoxifylline—Urticaria—Dexamethasone—psoriasis	6.08e-05	0.000511	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Prednisone—psoriasis	6.07e-05	0.000511	CcSEcCtD
Pentoxifylline—Dizziness—Prednisolone—psoriasis	6.07e-05	0.00051	CcSEcCtD
Pentoxifylline—Asthenia—Triamcinolone—psoriasis	6.05e-05	0.000509	CcSEcCtD
Pentoxifylline—Abdominal pain—Dexamethasone—psoriasis	6.05e-05	0.000509	CcSEcCtD
Pentoxifylline—Abdominal pain—Betamethasone—psoriasis	6.05e-05	0.000509	CcSEcCtD
Pentoxifylline—Body temperature increased—Dexamethasone—psoriasis	6.05e-05	0.000509	CcSEcCtD
Pentoxifylline—Body temperature increased—Betamethasone—psoriasis	6.05e-05	0.000509	CcSEcCtD
Pentoxifylline—NT5E—Metabolism—CARM1—psoriasis	6.05e-05	0.00398	CbGpPWpGaD
Pentoxifylline—Insomnia—Prednisone—psoriasis	6.03e-05	0.000507	CcSEcCtD
Pentoxifylline—Nausea—Cyclosporine—psoriasis	5.99e-05	0.000504	CcSEcCtD
Pentoxifylline—ADORA1—Circadian rythm related genes—NOS2—psoriasis	5.98e-05	0.00393	CbGpPWpGaD
Pentoxifylline—Pruritus—Triamcinolone—psoriasis	5.97e-05	0.000502	CcSEcCtD
Pentoxifylline—Dizziness—Hydrocortisone—psoriasis	5.92e-05	0.000498	CcSEcCtD
Pentoxifylline—Convulsion—Methotrexate—psoriasis	5.91e-05	0.000497	CcSEcCtD
Pentoxifylline—Dyspepsia—Prednisone—psoriasis	5.87e-05	0.000493	CcSEcCtD
Pentoxifylline—Nausea—Mycophenolate mofetil—psoriasis	5.84e-05	0.000491	CcSEcCtD
Pentoxifylline—Myalgia—Methotrexate—psoriasis	5.81e-05	0.000489	CcSEcCtD
Pentoxifylline—Chest pain—Methotrexate—psoriasis	5.81e-05	0.000489	CcSEcCtD
Pentoxifylline—Decreased appetite—Prednisone—psoriasis	5.79e-05	0.000487	CcSEcCtD
Pentoxifylline—ADORA2B—Signaling Pathways—HCAR2—psoriasis	5.79e-05	0.00381	CbGpPWpGaD
Pentoxifylline—Rash—Prednisolone—psoriasis	5.78e-05	0.000486	CcSEcCtD
Pentoxifylline—Dermatitis—Prednisolone—psoriasis	5.78e-05	0.000486	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5.77e-05	0.000485	CcSEcCtD
Pentoxifylline—CYP1A2—Tryptophan metabolism—CAT—psoriasis	5.76e-05	0.00378	CbGpPWpGaD
Pentoxifylline—Headache—Prednisolone—psoriasis	5.75e-05	0.000483	CcSEcCtD
Pentoxifylline—Discomfort—Methotrexate—psoriasis	5.74e-05	0.000483	CcSEcCtD
Pentoxifylline—Constipation—Prednisone—psoriasis	5.7e-05	0.000479	CcSEcCtD
Pentoxifylline—Vomiting—Hydrocortisone—psoriasis	5.7e-05	0.000479	CcSEcCtD
Pentoxifylline—Rash—Hydrocortisone—psoriasis	5.65e-05	0.000475	CcSEcCtD
Pentoxifylline—Dermatitis—Hydrocortisone—psoriasis	5.64e-05	0.000475	CcSEcCtD
Pentoxifylline—Confusional state—Methotrexate—psoriasis	5.62e-05	0.000472	CcSEcCtD
Pentoxifylline—Headache—Hydrocortisone—psoriasis	5.61e-05	0.000472	CcSEcCtD
Pentoxifylline—ADORA2B—GPCR downstream signaling—CCL20—psoriasis	5.61e-05	0.00368	CbGpPWpGaD
Pentoxifylline—ADORA1—Circadian rythm related genes—PPARG—psoriasis	5.59e-05	0.00367	CbGpPWpGaD
Pentoxifylline—Dizziness—Triamcinolone—psoriasis	5.58e-05	0.000469	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Methotrexate—psoriasis	5.57e-05	0.000469	CcSEcCtD
Pentoxifylline—Infection—Methotrexate—psoriasis	5.53e-05	0.000465	CcSEcCtD
Pentoxifylline—Feeling abnormal—Prednisone—psoriasis	5.49e-05	0.000462	CcSEcCtD
Pentoxifylline—Asthenia—Dexamethasone—psoriasis	5.49e-05	0.000462	CcSEcCtD
Pentoxifylline—Asthenia—Betamethasone—psoriasis	5.49e-05	0.000462	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Methotrexate—psoriasis	5.45e-05	0.000459	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Prednisone—psoriasis	5.45e-05	0.000458	CcSEcCtD
Pentoxifylline—Nausea—Prednisolone—psoriasis	5.45e-05	0.000458	CcSEcCtD
Pentoxifylline—Pruritus—Dexamethasone—psoriasis	5.42e-05	0.000455	CcSEcCtD
Pentoxifylline—Pruritus—Betamethasone—psoriasis	5.42e-05	0.000455	CcSEcCtD
Pentoxifylline—Skin disorder—Methotrexate—psoriasis	5.41e-05	0.000455	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Methotrexate—psoriasis	5.39e-05	0.000453	CcSEcCtD
Pentoxifylline—Vomiting—Triamcinolone—psoriasis	5.36e-05	0.000451	CcSEcCtD
Pentoxifylline—Nausea—Hydrocortisone—psoriasis	5.32e-05	0.000448	CcSEcCtD
Pentoxifylline—Rash—Triamcinolone—psoriasis	5.32e-05	0.000447	CcSEcCtD
Pentoxifylline—Dermatitis—Triamcinolone—psoriasis	5.31e-05	0.000447	CcSEcCtD
Pentoxifylline—Anorexia—Methotrexate—psoriasis	5.31e-05	0.000447	CcSEcCtD
Pentoxifylline—Urticaria—Prednisone—psoriasis	5.3e-05	0.000445	CcSEcCtD
Pentoxifylline—Headache—Triamcinolone—psoriasis	5.28e-05	0.000444	CcSEcCtD
Pentoxifylline—Body temperature increased—Prednisone—psoriasis	5.27e-05	0.000443	CcSEcCtD
Pentoxifylline—Abdominal pain—Prednisone—psoriasis	5.27e-05	0.000443	CcSEcCtD
Pentoxifylline—PDE4A—Signaling Pathways—HCAR2—psoriasis	5.26e-05	0.00346	CbGpPWpGaD
Pentoxifylline—Diarrhoea—Dexamethasone—psoriasis	5.24e-05	0.00044	CcSEcCtD
Pentoxifylline—Diarrhoea—Betamethasone—psoriasis	5.24e-05	0.00044	CcSEcCtD
Pentoxifylline—Hypotension—Methotrexate—psoriasis	5.21e-05	0.000438	CcSEcCtD
Pentoxifylline—ADORA2B—Signaling by GPCR—CCL20—psoriasis	5.09e-05	0.00335	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—CCL20—psoriasis	5.09e-05	0.00335	CbGpPWpGaD
Pentoxifylline—Musculoskeletal discomfort—Methotrexate—psoriasis	5.08e-05	0.000427	CcSEcCtD
Pentoxifylline—Dizziness—Dexamethasone—psoriasis	5.06e-05	0.000426	CcSEcCtD
Pentoxifylline—Dizziness—Betamethasone—psoriasis	5.06e-05	0.000426	CcSEcCtD
Pentoxifylline—Insomnia—Methotrexate—psoriasis	5.04e-05	0.000424	CcSEcCtD
Pentoxifylline—PDE5A—Hemostasis—NOS2—psoriasis	5.03e-05	0.00331	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TAGAP—psoriasis	5.02e-05	0.0033	CbGpPWpGaD
Pentoxifylline—Nausea—Triamcinolone—psoriasis	5.01e-05	0.000421	CcSEcCtD
Pentoxifylline—Dyspnoea—Methotrexate—psoriasis	4.97e-05	0.000418	CcSEcCtD
Pentoxifylline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.96e-05	0.00326	CbGpPWpGaD
Pentoxifylline—ADORA2A—Circadian rythm related genes—LEP—psoriasis	4.95e-05	0.00326	CbGpPWpGaD
Pentoxifylline—Somnolence—Methotrexate—psoriasis	4.95e-05	0.000417	CcSEcCtD
Pentoxifylline—ADORA1—Signaling Pathways—HCAR2—psoriasis	4.92e-05	0.00324	CbGpPWpGaD
Pentoxifylline—Hypersensitivity—Prednisone—psoriasis	4.91e-05	0.000413	CcSEcCtD
Pentoxifylline—Dyspepsia—Methotrexate—psoriasis	4.9e-05	0.000412	CcSEcCtD
Pentoxifylline—Vomiting—Betamethasone—psoriasis	4.87e-05	0.000409	CcSEcCtD
Pentoxifylline—Vomiting—Dexamethasone—psoriasis	4.87e-05	0.000409	CcSEcCtD
Pentoxifylline—PDE4B—Signaling Pathways—HCAR2—psoriasis	4.86e-05	0.0032	CbGpPWpGaD
Pentoxifylline—Decreased appetite—Methotrexate—psoriasis	4.84e-05	0.000407	CcSEcCtD
Pentoxifylline—Rash—Betamethasone—psoriasis	4.83e-05	0.000406	CcSEcCtD
Pentoxifylline—Rash—Dexamethasone—psoriasis	4.83e-05	0.000406	CcSEcCtD
Pentoxifylline—Dermatitis—Betamethasone—psoriasis	4.82e-05	0.000406	CcSEcCtD
Pentoxifylline—Dermatitis—Dexamethasone—psoriasis	4.82e-05	0.000406	CcSEcCtD
Pentoxifylline—PDE4B—Myometrial Relaxation and Contraction Pathways—JUN—psoriasis	4.82e-05	0.00317	CbGpPWpGaD
Pentoxifylline—Headache—Dexamethasone—psoriasis	4.8e-05	0.000403	CcSEcCtD
Pentoxifylline—Headache—Betamethasone—psoriasis	4.8e-05	0.000403	CcSEcCtD
Pentoxifylline—Asthenia—Prednisone—psoriasis	4.78e-05	0.000402	CcSEcCtD
Pentoxifylline—ADORA1—GPCR downstream signaling—CCL20—psoriasis	4.77e-05	0.00313	CbGpPWpGaD
Pentoxifylline—Pruritus—Prednisone—psoriasis	4.72e-05	0.000397	CcSEcCtD
Pentoxifylline—PDE4B—GPCR downstream signaling—CCL20—psoriasis	4.71e-05	0.0031	CbGpPWpGaD
Pentoxifylline—PDE4B—Myometrial Relaxation and Contraction Pathways—NFKB1—psoriasis	4.64e-05	0.00305	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—CCL20—psoriasis	4.62e-05	0.00304	CbGpPWpGaD
Pentoxifylline—ADORA2A—Circadian rythm related genes—NOS2—psoriasis	4.62e-05	0.00303	CbGpPWpGaD
Pentoxifylline—Feeling abnormal—Methotrexate—psoriasis	4.59e-05	0.000386	CcSEcCtD
Pentoxifylline—Diarrhoea—Prednisone—psoriasis	4.56e-05	0.000384	CcSEcCtD
Pentoxifylline—PDE4A—Signaling Pathways—TAGAP—psoriasis	4.56e-05	0.003	CbGpPWpGaD
Pentoxifylline—Gastrointestinal pain—Methotrexate—psoriasis	4.56e-05	0.000383	CcSEcCtD
Pentoxifylline—Nausea—Dexamethasone—psoriasis	4.55e-05	0.000382	CcSEcCtD
Pentoxifylline—Nausea—Betamethasone—psoriasis	4.55e-05	0.000382	CcSEcCtD
Pentoxifylline—Urticaria—Methotrexate—psoriasis	4.43e-05	0.000372	CcSEcCtD
Pentoxifylline—Dizziness—Prednisone—psoriasis	4.41e-05	0.000371	CcSEcCtD
Pentoxifylline—Body temperature increased—Methotrexate—psoriasis	4.4e-05	0.00037	CcSEcCtD
Pentoxifylline—Abdominal pain—Methotrexate—psoriasis	4.4e-05	0.00037	CcSEcCtD
Pentoxifylline—ADORA1—Signaling by GPCR—CCL20—psoriasis	4.33e-05	0.00285	CbGpPWpGaD
Pentoxifylline—ADORA2A—Circadian rythm related genes—PPARG—psoriasis	4.31e-05	0.00284	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—CCL20—psoriasis	4.28e-05	0.00281	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TAGAP—psoriasis	4.27e-05	0.00281	CbGpPWpGaD
Pentoxifylline—Vomiting—Prednisone—psoriasis	4.24e-05	0.000356	CcSEcCtD
Pentoxifylline—PDE4B—Signaling Pathways—TAGAP—psoriasis	4.22e-05	0.00277	CbGpPWpGaD
Pentoxifylline—Rash—Prednisone—psoriasis	4.2e-05	0.000353	CcSEcCtD
Pentoxifylline—Dermatitis—Prednisone—psoriasis	4.2e-05	0.000353	CcSEcCtD
Pentoxifylline—Headache—Prednisone—psoriasis	4.18e-05	0.000351	CcSEcCtD
Pentoxifylline—Hypersensitivity—Methotrexate—psoriasis	4.1e-05	0.000345	CcSEcCtD
Pentoxifylline—Asthenia—Methotrexate—psoriasis	4e-05	0.000336	CcSEcCtD
Pentoxifylline—ADORA1—Circadian rythm related genes—JUN—psoriasis	3.96e-05	0.00261	CbGpPWpGaD
Pentoxifylline—Nausea—Prednisone—psoriasis	3.96e-05	0.000333	CcSEcCtD
Pentoxifylline—Pruritus—Methotrexate—psoriasis	3.94e-05	0.000331	CcSEcCtD
Pentoxifylline—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	3.85e-05	0.00253	CbGpPWpGaD
Pentoxifylline—Diarrhoea—Methotrexate—psoriasis	3.81e-05	0.000321	CcSEcCtD
Pentoxifylline—ADORA2A—Signaling Pathways—HCAR2—psoriasis	3.8e-05	0.0025	CbGpPWpGaD
Pentoxifylline—ADORA1—G alpha (i) signalling events—CXCL8—psoriasis	3.76e-05	0.00247	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—CAT—psoriasis	3.72e-05	0.00245	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—TYK2—psoriasis	3.71e-05	0.00244	CbGpPWpGaD
Pentoxifylline—Dizziness—Methotrexate—psoriasis	3.68e-05	0.00031	CcSEcCtD
Pentoxifylline—ADORA2A—GPCR downstream signaling—CCL20—psoriasis	3.68e-05	0.00242	CbGpPWpGaD
Pentoxifylline—Vomiting—Methotrexate—psoriasis	3.54e-05	0.000298	CcSEcCtD
Pentoxifylline—ADORA2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.52e-05	0.00231	CbGpPWpGaD
Pentoxifylline—Rash—Methotrexate—psoriasis	3.51e-05	0.000295	CcSEcCtD
Pentoxifylline—Dermatitis—Methotrexate—psoriasis	3.51e-05	0.000295	CcSEcCtD
Pentoxifylline—Headache—Methotrexate—psoriasis	3.49e-05	0.000294	CcSEcCtD
Pentoxifylline—ADORA2A—Signaling by NGF—NFKBIA—psoriasis	3.48e-05	0.00229	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—CCL20—psoriasis	3.34e-05	0.0022	CbGpPWpGaD
Pentoxifylline—Nausea—Methotrexate—psoriasis	3.31e-05	0.000278	CcSEcCtD
Pentoxifylline—ADORA2A—Signaling Pathways—TAGAP—psoriasis	3.3e-05	0.00217	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	3.2e-05	0.0021	CbGpPWpGaD
Pentoxifylline—ADORA2A—Circadian rythm related genes—JUN—psoriasis	3.06e-05	0.00201	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CCL20—psoriasis	3.01e-05	0.00198	CbGpPWpGaD
Pentoxifylline—ADORA1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.99e-05	0.00197	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—VEGFA—psoriasis	2.92e-05	0.00192	CbGpPWpGaD
Pentoxifylline—PDE4B—Myometrial Relaxation and Contraction Pathways—IL6—psoriasis	2.91e-05	0.00191	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—APOE—psoriasis	2.89e-05	0.0019	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—TYK2—psoriasis	2.85e-05	0.00187	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	2.76e-05	0.00182	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CCL20—psoriasis	2.73e-05	0.0018	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR ligand binding—CXCL8—psoriasis	2.68e-05	0.00176	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	2.66e-05	0.00175	CbGpPWpGaD
Pentoxifylline—ADORA1—Circadian rythm related genes—TP53—psoriasis	2.62e-05	0.00172	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	2.6e-05	0.00171	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CCL20—psoriasis	2.56e-05	0.00168	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CCL20—psoriasis	2.53e-05	0.00166	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—PPARG—psoriasis	2.52e-05	0.00165	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	2.41e-05	0.00159	CbGpPWpGaD
Pentoxifylline—ADORA1—Circadian rythm related genes—IL6—psoriasis	2.39e-05	0.00157	CbGpPWpGaD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.31e-05	0.00152	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR ligand binding—CXCL8—psoriasis	2.28e-05	0.0015	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—NFKB1—psoriasis	2.22e-05	0.00146	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—TP53—psoriasis	2.2e-05	0.00145	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.07e-05	0.00136	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.07e-05	0.00136	CbGpPWpGaD
Pentoxifylline—ADORA2A—Circadian rythm related genes—TP53—psoriasis	2.02e-05	0.00133	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—STAT3—psoriasis	2e-05	0.00131	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCL20—psoriasis	1.97e-05	0.0013	CbGpPWpGaD
Pentoxifylline—ADORA2A—Circadian rythm related genes—IL6—psoriasis	1.85e-05	0.00122	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	1.81e-05	0.00119	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR ligand binding—CXCL8—psoriasis	1.76e-05	0.00116	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—SOCS1—psoriasis	1.66e-05	0.00109	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—TYK2—psoriasis	1.58e-05	0.00104	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—CXCL8—psoriasis	1.51e-05	0.000995	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—SOCS1—psoriasis	1.5e-05	0.000988	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—TYK2—psoriasis	1.43e-05	0.000942	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—SOCS1—psoriasis	1.41e-05	0.000926	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—IL6—psoriasis	1.39e-05	0.000917	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—SOCS1—psoriasis	1.39e-05	0.000915	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—CXCL8—psoriasis	1.37e-05	0.000904	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—CXCL8—psoriasis	1.37e-05	0.000904	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—TYK2—psoriasis	1.34e-05	0.000882	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NDUFA5—psoriasis	1.34e-05	0.000882	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—TYK2—psoriasis	1.33e-05	0.000872	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—CXCL8—psoriasis	1.29e-05	0.000846	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—CXCL8—psoriasis	1.27e-05	0.000836	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.25e-05	0.000822	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—CXCL8—psoriasis	1.25e-05	0.000821	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—APOE—psoriasis	1.22e-05	0.000803	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—LEP—psoriasis	1.22e-05	0.000803	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—CXCL8—psoriasis	1.17e-05	0.000768	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—CXCL8—psoriasis	1.16e-05	0.000759	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP2S1—psoriasis	1.14e-05	0.00075	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—NFKBIA—psoriasis	1.14e-05	0.000749	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—LEP—psoriasis	1.11e-05	0.000729	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—APOE—psoriasis	1.11e-05	0.000729	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SOCS1—psoriasis	1.09e-05	0.000715	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—APOE—psoriasis	1.04e-05	0.000683	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—LEP—psoriasis	1.04e-05	0.000683	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—TYK2—psoriasis	1.04e-05	0.000681	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—NFKBIA—psoriasis	1.03e-05	0.00068	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—APOE—psoriasis	1.03e-05	0.000675	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—LEP—psoriasis	1.03e-05	0.000675	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—CXCL8—psoriasis	9.94e-06	0.000653	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—NFKBIA—psoriasis	9.68e-06	0.000636	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—NFKBIA—psoriasis	9.57e-06	0.000629	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TYK2—psoriasis	9.33e-06	0.000613	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—CXCL8—psoriasis	9.03e-06	0.000593	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TYK2—psoriasis	8.47e-06	0.000557	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CXCL8—psoriasis	8.12e-06	0.000534	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—LEP—psoriasis	8.02e-06	0.000527	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—APOE—psoriasis	8.02e-06	0.000527	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TYK2—psoriasis	7.93e-06	0.000521	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TYK2—psoriasis	7.84e-06	0.000515	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—IL6—psoriasis	7.72e-06	0.000508	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—JUN—psoriasis	7.55e-06	0.000496	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NFKBIA—psoriasis	7.48e-06	0.000491	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CXCL8—psoriasis	7.37e-06	0.000485	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—NFKB1—psoriasis	7.27e-06	0.000478	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—IL6—psoriasis	7.01e-06	0.000461	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CXCL8—psoriasis	6.91e-06	0.000454	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—JUN—psoriasis	6.86e-06	0.000451	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CXCL8—psoriasis	6.82e-06	0.000449	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—NFKB1—psoriasis	6.6e-06	0.000434	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—VEGFA—psoriasis	6.6e-06	0.000434	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—IL6—psoriasis	6.57e-06	0.000432	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—STAT3—psoriasis	6.53e-06	0.000429	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—IL6—psoriasis	6.49e-06	0.000426	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—JUN—psoriasis	6.42e-06	0.000422	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—JUN—psoriasis	6.34e-06	0.000417	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—NFKB1—psoriasis	6.18e-06	0.000406	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TYK2—psoriasis	6.12e-06	0.000403	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—NFKB1—psoriasis	6.11e-06	0.000401	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—VEGFA—psoriasis	5.99e-06	0.000394	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.98e-06	0.000393	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—STAT3—psoriasis	5.93e-06	0.00039	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—VEGFA—psoriasis	5.61e-06	0.000369	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CARM1—psoriasis	5.57e-06	0.000366	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—STAT3—psoriasis	5.55e-06	0.000365	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—VEGFA—psoriasis	5.54e-06	0.000364	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—STAT3—psoriasis	5.49e-06	0.000361	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CXCL8—psoriasis	5.33e-06	0.00035	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.21e-06	0.000342	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—IL6—psoriasis	5.07e-06	0.000333	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TP53—psoriasis	4.98e-06	0.000328	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—JUN—psoriasis	4.96e-06	0.000326	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NFKB1—psoriasis	4.77e-06	0.000314	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IL6—psoriasis	4.56e-06	0.0003	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TP53—psoriasis	4.53e-06	0.000297	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—VEGFA—psoriasis	4.33e-06	0.000285	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—STAT3—psoriasis	4.29e-06	0.000282	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TP53—psoriasis	4.24e-06	0.000279	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TP53—psoriasis	4.19e-06	0.000275	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IL6—psoriasis	4.14e-06	0.000272	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IL6—psoriasis	3.88e-06	0.000255	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IL6—psoriasis	3.83e-06	0.000252	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CAT—psoriasis	3.43e-06	0.000225	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TP53—psoriasis	3.27e-06	0.000215	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IL6—psoriasis	2.99e-06	0.000197	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOE—psoriasis	2.66e-06	0.000175	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPARG—psoriasis	2.32e-06	0.000152	CbGpPWpGaD
